The company is a fully integrated, holistic nutrition provider and market leader in customised micronutrient formulations, offering products from premixes to therapeutic and clinical solutions. Its end-to-end operations from R&D and manufacturing to marketing enable consistent quality, food safety, and scalable solutions across preventive and therapeutic nutrition categories
The company has developed in-house brands like PENTASURE, OBESIGO, and PEDIAGOLD for specialised therapy areas and operates globally across 70+ countries with three manufacturing facilities and two R&D centres in India. It is a leading premix provider in India and a major licensed supplier of micronutrient powders under UN programs, supporting food fortification and public health initiatives
The company has pan-India omnichannel distribution through retail pharmacies, hospitals, e-commerce, online pharmacies, and its own brand websites, with exports to over 20 countries. Its network includes 342+ distributors and a 157-member sales force reaching 15,000+ healthcare professionals, contributing ~6% of FY25 revenue via online sales
The company faces risks from counterfeit and look-alike products, particularly in India, which may harm brand reputation, customer trust, and financial performance. Unauthorised replication of its proprietary formulations or branded products could undermine innovation, differentiation, and R&D investments
The company’s operations are subject to evolving health, safety, and environmental laws regulating manufacturing, waste management, and emissions. Non-compliance or exceeding permitted discharge levels could result in liabilities, remediation costs, and penalties from the government or third parties
The company maintains confidentiality over product recipes, formulations, pricing, and launch information to protect its competitive position. Any unauthorised disclosure, despite employee agreements, could undermine its market advantage and adversely impact business performance
Also called a profit and loss statement, an income statement shows a company’s income, expenses, and how much profit or loss it has made over a specific accounting period. It provides a clear view of how well the business is running.
| Particulars (in Cr) | Mar 2025 | Y/Y Change |
|---|---|---|
| Operating Revenue | 324.93 | +9.14% |
| Other Income | 6.36 | -7.69% |
| Total Income | 331.29 | +8.76% |
| Total Expenditure | 296.78 | +3.96% |
| EBIDT | 47.22 | +50.38% |
| Depreciation | 8.77 | +8.00% |
| Interest | 3.95 | -4.82% |
| Tax | 9.34 | +28.12% |
| Net Profit | 24.38 | +99.67% |
A balance sheet is a financial statement that details a company’s assets, liabilities, and shareholders’ equity at a given time. It helps assess how financially strong and stable the company is.
| Particulars (in Cr) | Mar 2025 |
|---|---|
| Total Current Assets | 183.64 |
| Total Non-Current Assets | 77.72 |
| Fixed assets | 68.30 |
| Total Assets | 261.36 |
| Total Current liabilities | 52.66 |
| Total Non Current Liabilities | 14.51 |
| Total Equity Plus Liabilities | 261.36 |
| Total Shareholder Funds | 181.97 |
| Total Debt to Equity | 15.00% |
Cash flow highlights the cash or cash equivalents moving in and out of a company during a particular period. It provides a clear picture of how well a company manages its cash by tracking its operating, investing and financing activities.
| Particulars (in Cr) | Mar 2025 |
|---|---|
| Cash from Operating Activity | 37.79 |
| Cash from Financing Activities | -19.24 |
| Cash from Investing Activities | -22.68 |
| Net Cash Flow | -4.13 |
Hexagon Nutrition was incorporated on May 27, 1993. Hexagon Nutrition is a research-oriented pure-play nutrition company. The company offers products like clinical products, micronutrient premixes and therapeutic products. Their product portfolio addresses a broad spectrum of aspects such as fortification of foods, therapeutic nutrition, clinical nutrition and alleviation of malnutrition.
